Revivo Biosystems

What Revivo Biosystems does

Revivo Biosystems is a Singapore-headquartered private company that develops and commercializes an organ-on-a-chip platform with simulated blood flow, marketed as 4D human tissue testing for cosmetics, personal care, and pharmaceutical R&D laboratories. The platform centers on two proprietary hardware products — ReleGO™, an automated fraction collector that runs up to 12 human skin biopsies or organotypic cultures simultaneously under programmable flow conditions (0.5–120 µL/min), and REVex™, a credit-card-sized microfluidic chip compatible with human explants and commercial reconstructed skin substitutes — alongside proprietary tissue models such as the Chronological Aging Skin Model (REVskin). The company monetizes through capital equipment sales and contract testing services (permeation, wound healing, aging studies, OECD TG 431/432/439/498 safety assays, and clinical in-vivo studies), distributed via a network of 11 regional channel partners and direct sales from Singapore.

The company originated as a spin-off from A*STAR, with the founding team having invented the underlying explants-on-chip and skin-on-chip technology at the Singapore Institute of Manufacturing Technology (SIMTech) and the Institute of Medical Biology (IMB). Revivo positions its offering against traditional Franz Diffusion cell testing, claiming 10x savings on manpower and biomaterial, up to 2x longer tissue viability, and significantly higher precision at flow rates down to 0.5 µL/min. Its primary customer segments are cosmetics and personal care brands (safety, efficacy, permeation, and anti-aging claim support), pharmaceutical and biotech companies (preclinical safety/efficacy), and chemical/ingredient manufacturers. In 2024 the ReleGO instrument earned CE and KC marks, the company entered a strategic collaboration with French biotech group WEPREDIC, and its Chronological Aging Skin Model won the COSMETIC 360 Outstanding Innovation Award — together indicating a focused scale-up across Europe and Asia-Pacific on a lean operating footprint.

Name

Revivo Biosystems

Legal name

REVIVO BioSystems

Website

https://revivobio.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Revivo Biosystems sells organ-on-a-chip hardware (ReleGO fraction collector, REVex microfluidic chip) and 4D tissue testing services for cosmetics, personal care, pharmaceutical, and chemical R&D laboratories seeking animal-cruelty-free safety, permeation, and efficacy data.

Ownership category

akta.pro rank

Product category

Organ-on-Chip Testing Equipment

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511)

SIC

Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

Keywords

• Organ-on-chip platforms
• Microfluidic tissue testing
• In vitro skin models
• Preclinical safety testing
• Permeation testing equipment

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Product Sales (ReleGO and REVex): Sale of the ReleGO automated fraction collector system and REVex microfluidic chips. Products are sold directly and through a network of regional distributors across 11 regions including Asia-Pacific and Europe. Products carry CE and KC certifications for market access.
2. Testing Services: Contract testing services including 4D in-vitro and ex-vivo testing, permeation studies, wound healing studies, chronological aging model studies, safety tests, efficacy tests, and clinical testing services. The company provides commercial strategy and project execution services alongside testing.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Core offering

Revivo Biosystems develops and sells an organ-on-chip platform for in vitro and ex vivo testing of human skin tissues, comprising two core hardware products — the ReleGO™ automated fraction collector and the REVex™ microfluidic chip — which together mimic blood flow to create in vivo-like 4D tissue conditions. The company also provides contract testing services (permeation, wound healing, chronological aging, 2D/3D safety tests per OECD guidelines, and clinical testing) for cosmetics, personal care, pharmaceutical and chemical-industry research labs.

Product overview

REVIVO BioSystems offers a unified 4D human tissue testing platform consisting of two core hardware products: ReleGO™ (automated fraction collector) and REVex™ Chip (microfluidic device). The platform uses organ-on-a-chip technology to mimic blood flow function for realistic in vitro and ex vivo testing of skin tissues. Additional services include permeation testing, wound healing studies, chronological aging models, and standardized 2D/3D safety and efficacy tests compliant with OECD guidelines. The company also provides clinical testing services for in vivo studies.

Differentiator

Problem solved

Functional benefit

Brands

• ReleGO™: Automated fraction collector - a fully automated and programmable system that mimics the function of blood flow for in vivo-like conditions in tissue testing.
• REVex™
• REVskin™

Products and services

• ReleGO™ Automated Fraction Collector Automated, programmable fraction collector with temperature control and fluidic handling that mimics the function of blood flow to create in vivo-like conditions for 4D human tissue testing; supports up to 12 human skin biopsies, synthetic membranes, or 2D/3D organotypic cultures run simultaneously with flow rates from 0.5 to 120 uL/min. Sold to cosmetics, personal-care, pharma and chemical-industry research labs via direct sales and a 10-region distributor network; CE and KC certified.
• REVex™ Microfluidic Chip Miniature credit-card-sized microfluidic device compatible with human explants and commercial reconstructed skin substitutes, with built-in bubble traps, laminar flow promotion, and continuous receptor fluid flow for permeation studies and in vitro release testing (IVRT). Sold to cosmetics, personal-care, pharma and chemical-industry research labs.
• 4D In-vitro & Ex-vivo Testing Services Comprehensive contract testing services using the 4D organ-on-a-chip platform for permeation studies, wound healing studies, chronological aging studies, and mechanistic safety and efficacy testing. Delivered to cosmetics, personal-care, pharma, biotech, and chemical-manufacturer clients.
• Chronological Aging Skin Model (REVskin™) Proprietary non-oxidative-stress aging testing model that uses the perfusing 4D platform to stimulate tissue aging and study treatments aimed at preserving skin cell proliferation and stemness. Delivered to cosmetics and personal-care R&D teams seeking differentiated anti-aging claim support.
• 2D In-vitro Safety Testing Services In vitro safety testing services including 3T3 Neutral Red Uptake Toxicity (OECD 432) and Cytotoxicity on Human Epithelial Keratinocytes (HEKs). Sold to cosmetics, personal-care, chemical and pharmaceutical safety testing teams.
• 3D In-vitro Safety Testing Services In vitro safety testing services including Skin Irritation (OECD TG 439), Skin Corrosion (OECD TG 431), and Phototoxicity (OECD TG 498). Sold to cosmetics, personal-care, chemical and pharmaceutical safety testing teams.
• Clinical Testing Services (In-vivo) Clinical safety and efficacy testing services including Skin Irritation Test, Skin Sensitization Test, Comprehensive Skin Efficacy Test, Non-Comedogenic Test, and Anti-Acne Test, with per-sample quoting and turnaround times of 3–4.5 months. Sold to cosmetics and personal-care brands for claim support and regulatory submissions.

Quantifiable outcome

• 10x savings on manpower and biomaterial compared to traditional testing methods
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Five partnerships are on record, tiered core, founding and minor.

• WEPREDICcoreStrategic or Co-development Partner · 27 September 2024A strategic collaboration with WEPREDIC, a leading French biotech group specializing in advanced solutions for assessing the safety and efficacy of pharmaceuticals, cosmetics, and industrial compounds. The collaboration aims to leverage combined expertise and products to bring innovative solutions to market and explore commercial opportunities across Europe and beyond.
• A*STAR (Agency for Science, Technology and Research)foundingTechnology or IntegrationREVIVO BioSystems is a spin-off from A*STAR. The founding team invented and developed the company's organ-on-a-chip platform of explants-on-chip and skin-on-chip technology at the Singapore Institute of Manufacturing Technology (SIMTech) and the Institute of Medical Biology in A*STAR. A 2014 Skin-on-Chip research program was the genesis of the company.
• Biopredic InternationalcoreChannel Partner/ Reseller/ DistributorBiopredic International is listed as a partner and distributor of REVIVO BioSystems, representing the company in distribution networks.
• EvonikcoreStrategic or Co-development PartnerEvonik is listed as a partner of REVIVO BioSystems, suggesting a strategic relationship in the personal care and cosmetics testing space.
• 5HT Digital HubminorGTM or Marketing Partner5HT Digital Hub Chemistry Health is listed as a partner and has featured REVIVO BioSystems content on their media platform.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Emulate: Emulate is a leading organ-on-chip platform company commercializing organ-chips (Liver-Chip, Lung-Chip, etc.) for drug development and safety testing. It is directly comparable to Revivo as a competing organ-on-chip platform player targeting pharma and consumer products research customers.
• Mimetas: Mimetas is a Netherlands-based organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models used in pharma and cosmetics testing. Directly comparable to Revivo's microfluidic organ-on-chip offering with overlapping customer base in cosmetics safety/efficacy.
• TissUse: TissUse is a German organ-on-chip company developing multi-organ-chip (MOC) platforms for cosmetics, pharma, and chemical testing. Directly comparable to Revivo's microfluidic skin-on-chip platform with overlapping applications in cosmetics ingredient testing and OECD-compliant safety assays.
• CN Bio: CN Bio is a UK-based organ-on-chip company offering PhysioMimix platforms for liver and other organ models used in drug discovery. Directly comparable as an organ-on-chip platform competitor, with overlap in microphysiological systems and pharma/consumer products testing applications.
• InSphero: InSphero is a Swiss 3D organoid/microtissue company offering liver, pancreatic, and other tissue models for drug safety and efficacy testing. Closely comparable to Revivo in delivering validated in vitro tissue models to pharma and cosmetics customers, though focused on organoid rather than microfluidic chip architecture.

Broad incumbents

• MatTek Life Sciences: MatTek is an established US-based reconstructed human skin tissue model company (EpiDerm, Melanoma) widely used for OECD-compliant safety testing. Broad incumbent serving similar cosmetic/personal care safety testing customers as Revivo but with static 3D tissue models rather than dynamic microfluidic platforms.
• SkinEthic / Episkin (L'Oréal): SkinEthic (Episkin) is L'Oréal's reconstructed human epidermis division producing validated tissue models for safety/irritation testing. Broad incumbent in reconstructed skin models with deep institutional ties to L'Oréal — overlapping with Revivo's cosmetics customer base but backed by far larger R&D resources.
• CytoSMART (Lonza): CytoSMART (acquired by Lonza) provides live-cell imaging and microfluidic cell culture devices used in academic and industrial research. Broad incumbent with overlapping microfluidic instrument capability, though primarily imaging-focused rather than skin-tissue testing platforms.

Emerging players

• Hurel Corporation: Hurel is an early-stage organ-on-chip company focused on in vitro alternatives to animal testing for cosmetics and chemical safety. Emerging player with overlapping focus on animal-free alternatives but narrower platform scope than Revivo's microfluidic skin-on-chip system.
• Kirkstall: Kirkstall is a UK-based cell culture / organ-on-chip company offering Quasi Vivo interconnected multi-chamber systems for in vitro tissue modeling. Emerging player with comparable microfluidic multi-chamber architecture to Revivo's ReleGO/REVex, though broader in scope across organs rather than skin-specialized.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/revivo-biosystems

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revivo Biosystems